|
Daily Medical Update
Chronic Kidney Disease Evaluation
Tuesday, August 25, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Endocrinology, diabetes & metabolism (2026) - Network meta-analysis
Key Findings
- All evaluated pharmacologic classes were associated with reduced CKD progression versus placebo in 9 trials involving 37,749 participants.
- SGLT2 inhibitors had the most precise and highest-confidence estimate for CKD progression (HR 0.66, 95% CI 0.60-0.74).
- Treatment-related albuminuria reduction was not significantly associated with clinical kidney outcomes (R² = 0.007).
📋 Practice Implication: For diabetes-associated CKD, SGLT2 inhibitors have the strongest placebo-referenced progression evidence, while apparent class differences should not be treated as proof of superiority without direct comparisons.
|
Annals of internal medicine (2025) - Practice guideline
Key Findings
- The updated guideline increased primary-care coverage through 23 recommendations spanning CKD diagnosis, assessment, monitoring, management, and nephrology referral.
- Recommendations address hypertension, cardiovascular and kidney-risk-reducing pharmacotherapy, mortality, contrast-associated acute kidney injury prevention, and shared decision-making.
- New or updated medication guidance increased the available primary-care options to include ACE inhibitors or ARBs, SGLT2 inhibitors, GLP-1 receptor agonists, nonsteroidal mineralocorticoid receptor antagonists, and statins.
📋 Practice Implication: Primary care teams can use this guideline as a current framework for integrating CKD detection, monitoring, referral, and newer protective therapies into routine care.
|
Diabetes research and clinical practice (2026) - Systematic review and meta-analysis
Key Findings
- Among 59,018 CKD patients, higher HbA1c variability was associated with more cardiovascular events (HR 1.82, 95% CI 1.52-2.20).
- Higher HbA1c variability was also associated with greater all-cause mortality (HR 2.18, 95% CI 1.16-4.07).
- The association with CKD progression was not statistically significant (HR 1.49, 95% CI 0.87-2.55).
📋 Practice Implication: Glycemic variability may add prognostic information beyond average HbA1c for cardiovascular and mortality risk, but it is not yet established as an independent target for slowing renal progression.
|
Lancet (London, England) (2026) - Individual-participant data meta-analysis
Key Findings
- A 5 mm Hg reduction in systolic blood pressure reduced major cardiovascular disease in CKD (HR 0.91, 95% CI 0.87-0.94).
- Relative cardiovascular risk reduction was consistent across CKD stages, including severe stages 4-5, and across proteinuria and baseline blood-pressure categories.
- Benefit was attenuated in patients with CKD and coexisting diabetes (HR 0.96, 95% CI 0.90-1.02) compared with those without diabetes (HR 0.88, 95% CI 0.84-0.93).
📋 Practice Implication: Blood-pressure lowering remains broadly cardioprotective even in advanced CKD, but patients with diabetes may require individualized strategies because the relative benefit appears smaller.
|
Lancet (London, England) (2026) - Individual-participant data pooled analysis
Key Findings
- Across 14,574 participants, finerenone reduced the composite kidney outcome by 24% versus placebo (HR 0.76, 95% CI 0.68-0.86).
- Finerenone also reduced the composite cardiovascular outcome (HR 0.80, 95% CI 0.70-0.91), heart-failure hospitalization, cardiovascular death, and all-cause death (HR 0.88, 95% CI 0.79-0.99).
- Kidney-outcome benefits were consistent across glycemic status, CKD etiology, baseline eGFR, albuminuria, and SGLT2-inhibitor use; hyperkalemia increased but hospitalization was uncommon.
📋 Practice Implication: Finerenone offers kidney and cardiovascular protection across a broad CKD population, with potassium monitoring remaining the key safety consideration when incorporating it into foundational therapy.
|
|
💡
Summary
Recent evidence supports a layered approach to chronic kidney disease evaluation and management: guideline-directed primary care, blood-pressure lowering across CKD stages, and kidney- and cardiovascular-protective therapies such as SGLT2 inhibitors and finerenone. HbA1c variability identifies higher cardiovascular and mortality risk, although its role in renal progression remains uncertain.
|
|